This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … To take care of laboratory organization and related administrative tasks Competencies that are required for …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … To take care of laboratory organization and related administrative tasks To have a proven ability to effectively …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … with wet-lab scientists, technicians, project leads. Skills and competencies that are required for making …
… machinery. Axiomer® RNA editing technology harnesses ADAR(Adenosine Deaminase Acting on RNA), which is machinery … designing and implementing a new product planning process Leads new product planning, positioning, and pre-launch …